Literature DB >> 24613524

Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Paul V Licciardi1, Fiona M Russell2, Anne Balloch3, Robert L Burton4, Moon H Nahm4, Gwendolyn Gilbert5, Mimi L K Tang6, Edward K Mulholland7.   

Abstract

The impact of prior nasopharyngeal carriage on serotype-specific IgG responses following immunization with pneumococcal conjugate vaccines (PCV) has recently been described. This report extends these findings to describe the attenuation of functional immune responses following 23-valent pneumococcal polysaccharide vaccination (PPS). We report the attenuation of immune responses following booster with the 23-valent pneumococcal polysaccharide vaccination (PPS) in infants with prior nasopharyngeal carriage of Streptococcus pneumoniae. Fijian infants who were part of a phase II randomized, controlled trial of reduced dose PCV7 schedules were the basis of this study. Pneumococcal carriage was determined at 6, 9 and 12 months of age, prior to PPS immunization. Serum samples collected at 18 weeks (post-PCV7), 12 months (pre-PPS), 12.5 months and 17 months (post-PPS) of age were assessed for serotype-specific IgG and opsonophagocytic responses. The most frequently carried serotypes were 6B (N=11), 19F (N=14) and 23F (N=23). Significantly lower serotype-specific IgG for 19F, 23F but not 6B post-PPS were detected in infants with homologous serotype carriage prior to PPS compared with non-carriers (N=230). However, OPA levels for 6B and 23F were lower in infants that carried these serotypes. Pneumococcal carriage with 19F or 23F at any time prior to PPS immunization in infants at 12 months of age who were previously primed with PCV resulted in serotype-specific hyporesponsiveness that persisted until 17 months of age. These results may have implications for the timing of infant vaccine schedules, particularly in high disease burden settings.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carriage; Hyporesponsiveness; Opsonophagocytosis; PPS; Pneumococcal

Mesh:

Substances:

Year:  2014        PMID: 24613524      PMCID: PMC4019672          DOI: 10.1016/j.vaccine.2014.02.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance.

Authors:  A Balloch; P V Licciardi; A Leach; A Nurkka; M L K Tang
Journal:  Vaccine       Date:  2009-11-21       Impact factor: 3.641

Review 2.  Pathogenesis, treatment, and prevention of pneumococcal pneumonia.

Authors:  Tom van der Poll; Steven M Opal
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

3.  Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: a cohort study.

Authors:  Kerry-Ann F O'Grady; Katherine J Lee; John B Carlin; Paul J Torzillo; Anne B Chang; E Kim Mulholland; Stephen B Lambert; Ross M Andrews
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

Review 4.  Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

Authors:  Katherine L O'Brien; Michael Hochman; David Goldblatt
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

5.  Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study.

Authors:  Philip C Hill; Yin Bun Cheung; Abiodun Akisanya; Kawsu Sankareh; George Lahai; Brian M Greenwood; Richard A Adegbola
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

6.  Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

Authors:  F M Russell; A Balloch; M L K Tang; J R Carapetis; P Licciardi; J Nelson; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; G B Byrnes; Y B Cheung; E K Mulholland
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

7.  Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease.

Authors:  Ray Borrow; Elaine Stanford; Pauline Waight; Matthew Helbert; Paul Balmer; Rosalind Warrington; Mary Slack; Robert George; Elizabeth Miller
Journal:  Infect Immun       Date:  2008-09-08       Impact factor: 3.441

Review 8.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

Authors:  Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian
Journal:  Lancet       Date:  2009-09-12       Impact factor: 79.321

Review 9.  Reconsideration of the use of meningococcal polysaccharide vaccine.

Authors:  Dan M Granoff; Andrew J Pollard
Journal:  Pediatr Infect Dis J       Date:  2007-08       Impact factor: 2.129

10.  Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.

Authors:  Penny Salt; Carly Banner; Sarah Oh; Ly-mee Yu; Susan Lewis; Dingxin Pan; David Griffiths; Berne Ferry; Andrew Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-03-07
View more
  5 in total

Review 1.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

2.  Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.

Authors:  John Ojal; Laura L Hammitt; John Gaitho; J Anthony G Scott; David Goldblatt
Journal:  Vaccine       Date:  2017-07-21       Impact factor: 3.641

3.  A Nonfunctional Opsonic Antibody Response Frequently Occurs after Pneumococcal Pneumonia and Is Associated with Invasive Disease.

Authors:  Fabian Uddén; Jonas Ahl; Nils Littorin; Kristoffer Strålin; Simon Athlin; Kristian Riesbeck
Journal:  mSphere       Date:  2020-02-05       Impact factor: 4.389

4.  Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Authors:  Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Paul Licciardi; Sue Skull; Ross Andrews; Jonathan Carapetis; Joseph McDonnell; Vicki Krause; Peter Stanley Morris
Journal:  Vaccine X       Date:  2021-02-15

5.  Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians.

Authors:  Paul V Licciardi; Edwin Hoe; Zheng Quan Toh; Anne Balloch; Sarah Moberley; Paula Binks; Rachel Marimla; Amanda Leach; Sue Skull; Kim Mulholland; Ross Andrews
Journal:  Clin Transl Immunology       Date:  2017-10-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.